Agios Pharma stock rating downgraded by RBC Capital after mixed trial data

Investing.comWednesday, November 19, 2025 at 6:31:01 PM
Agios Pharma stock rating downgraded by RBC Capital after mixed trial data
  • RBC Capital has downgraded Agios Pharma's stock rating due to mixed results from recent clinical trials, indicating potential challenges for the company in achieving its objectives.
  • This downgrade could negatively impact investor confidence and the company's market position, suggesting that Agios Pharma may need to address the concerns raised by the trial data to regain trust and improve its stock performance.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results
NegativeFinancial Markets
Bank of America (BofA) has reduced its stock price target for Agios Pharma from $54 to $32 following disappointing results from a trial related to sickle cell disease (SCD). This downgrade reflects concerns about the company's future performance and market position.
WESCO International stock rating upgraded by RBC Capital on datacenter growth
PositiveFinancial Markets
WESCO International has received an upgraded stock rating from RBC Capital, driven by the anticipated growth in the datacenter sector. This positive sentiment reflects the company's potential to capitalize on increasing demand for datacenter infrastructure and services. RBC Capital's assessment suggests confidence in WESCO's ability to navigate market trends and leverage opportunities in this expanding industry, which is crucial for its future performance.